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Abstract
Increased Wnt signalling has been implicated in the aetiology of
many different human cancers, including breast cancers. In most
cases, Wnt signalling is thought to drive tumourigenesis through
the stabilisation of cytosolic β-catenin and the subsequent
changes in the expression of T-cell factor (TCF)-dependent genes.
However, this is not necessarily the only mechanism, as Wnt
proteins can signal through a number of different intracellular
signalling pathways. The ongoing work from Nancy Hynes’
laboratory continues to highlight this latter possibility.
In their most recent article in Breast Cancer Research,
Matsuda and colleagues [1] showed that expression of the
secreted Wnt antagonist secreted Frizzled-related protein
(sFRP)1 reduced the ability of the breast cancer cell line
MDA-MB-231 to form tumours in an orthotopic xenograft
model. Using micro-array analysis, they demonstrated that
sFRP1 downregulated Cyclin D1 expression, whilst
CDKN1A, which encodes the cell cycle regulator p21, was
upregulated, leading to an inhibition of proliferation. In
addition, they indicate that β1-integrin and the extracellular
matrix proteins fibronectin and laminin are downregulated,
which will also reduce proliferation as attachment to the
extracellular matrix is required to maintain the proliferative
potential of epithelial cells. Furthermore, they showed Wnt
signalling promoted cell migration and that sFRP1 inhibited
Wnt1-induced motility in a scratch-assay. In vivo, this anti-
migratory effect may contribute to the reduced ability of
sFRP1-expressing MDA-MB-231 cells to form lung
metastases when injected into the host bloodstream.
This recent paper builds upon previous work from the Hynes
group addressing the role of Wnt signalling in breast cancer.
They have shown that Wnt signalling in the HC11 immor-
talised mammary epithelial cell line induced an ErbB1/
Epidermal growth factor receptor (EGFR)-dependent activa-
tion of extracellular signal-regulated kinase (ERK) signalling
[2]. Consistently with this, the inhibition of autocrine Wnt
signalling in a panel of breast cancer cell lines led to a
reduction in ERK activity and a corresponding inhibition of
proliferation [3]. Interestingly, their work has suggested that
the activation of ErbB1/EGFR signalling was through a
β-catenin-independent mechanism.
Wnt1 was the first oncogene to be described in the
mammary gland [4] and its potency was reiterated by the
ability of Wnt1 to transform primary human mammary epi-
thelial cells alone, unlike the classical oncogenes encoding
Ras and SV40 large T antigen, which must act in combination
[5]. The aberrant activation of Wnt signalling in many
cancers, especially colorectal cancer, can be attributed to
elevated levels of cytosolic and nuclear β-catenin leading to
changes in the expression of TCF-dependent genes. This
occurs through mutations in components of the β-catenin
destruction complex or mutations in β-catenin itself that
prevent it from being targeted for proteosomal degradation
[6]. However, in breast cancer, such mutations are rare,
despite the clear nuclear accumulation of β-catenin in breast
cancer cells [7]. Instead, Wnt activation seems to occur at
the level of the Wnt ligand-receptor interaction, through the
upregulation of ligands and receptors and the downregulation
of secreted inhibitors [3,8,9]. This raises the possibility that
other Wnt pathways, in addition to β-catenin signalling, are
active in breast cancer.
Several distinct events can occur following Wnt-Frizzled
receptor binding, in addition to β-catenin stabilisation.
Although not fully characterised, these have been loosely
grouped into the ‘non-canonical’ pathways, which include the
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Wnt/Planar cell polarity (PCP) and the Wnt/protein kinase C
(PKC) pathways [10]. In their most recent paper, Matsuda
and colleagues make the link between Wnt signalling and
regulation of cell motility [1]. Many studies have shown a link
between Wnts and cell motility mediated by PCP signalling
[10]. This pathway requires Frizzled, but not Low density
lipoprotein receptor-related protein (LRP)5/6, and links
ligand-binding to the Rho family of small GTPases. Indeed,
Matsuda and colleagues suggest that the migratory effect of
Wnts can be blocked using a Rho kinase inhibitor [1].
Furthermore, Wnt/PKC signalling, which is also dependent
upon Frizzled and Dishevelled but not β-catenin, is clearly
linked to the metastatic potential of invasive melanoma [11],
although a role for this pathway in breast cancer has not yet
been reported. In light of this, it is very interesting that the
phenotypes of mammary tumours that arise from over-
expressing either Wnt proteins or stabilised forms of
β-catenin are different [12]. Although this difference could be
due to the secreted Wnt proteins signalling to neighbouring
tissues in a paracrine fashion, it could also represent the
effects of simultaneous activation of both β-catenin-
dependent and -independent pathways.
Given the ability of Wnt signalling to directly affect cellular
processes such as proliferation, differentiation and migration,
as well as its ability to activate signalling through other
oncogenic pathways such as ErbB1/EGFR [2,3], Notch
[5,13] and Hedgehog [12], it is no surprise then that
therapeutically targeting Wnt activity is so attractive. A recent
publication has identified several small molecule inhibitors of
Wnt signalling [14], one class of which affects production of
Wnt ligands. Breast cancer, in which excessive Wnt
signalling appears to be driven by ligand rather than
mutations in the β-catenin destruction complex, could be
particularly responsive to treatment with such inhibitors, as
well as with secreted inhibitors such as sFRPs, whose
efficacy was illustrated in this study [1]. The advantage of
inhibition at the level of the ligand would be to inhibit all β-
catenin-dependent and -independent effects of Wnt
signalling, including the PCP and PKC pathways.
The possibility that both β-catenin-dependent and -indepen-
dent Wnt signalling contribute to tumourigenesis in breast
cancer opens many new directions to study, and may provide
valuable therapeutic insights.
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